Literature DB >> 830408

Influence of adriamycin and adriamycin-radiation combination on jejunal proliferation in the mouse.

D R Burholt, R F Hagemann, L L Schenken, S Lesher.   

Abstract

The influence of adriamycin and adriamycin-radiation combinations on posttreatment proliferative activity of the mouse jejunum was examined by measuring [3H]thymidine incorporation. Single doses of 5 or 10 mg/kg produced a transient reduction in the proliferative activity, while 1 mg/kg had little effect. After 10 mg/kg, there was a rapid decrease in the number of mitotic figures, followed by a gradual decrease in the number of and rate of DNA synthesis in S-phase cells. A compensatory epithelial hyperplasia characterized by an enlarged crypt proliferative population and shortened mitotic cycle duration was observed beginning 48 hr after treatment. Multiple doses of adriamycin totalling 10 mg/kg inhibited cell production to a greater extent than the equivalent single dose. In combination with 1000 R, adriamycin (5 mg/kg) given from 96 hr before to 72 hr after irradiation reduced the amount of postirradiation proliferation.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 830408

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  3 in total

1.  Comparison of tritiated thymidine and metaphase arrest techniques of measuring cell production in rat intestine.

Authors:  J G Sharp; N A Wright
Journal:  Dig Dis Sci       Date:  1984-12       Impact factor: 3.199

2.  Interactions of radiation and adriamycin, bleomycin, mitomycin C or cis-diamminedichloroplatinum II in intestinal crypt cells.

Authors:  H von der Maase
Journal:  Br J Cancer       Date:  1984-06       Impact factor: 7.640

3.  Proliferative defects in renal and intestinal epithelium after cis-dichlorodiammine platinum (II).

Authors:  C J Kovacs; P G Braunschweiger; L L Schenken; D R Burholt
Journal:  Br J Cancer       Date:  1982-02       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.